Objective: To investigate value of nasal nitric oxide (nNO) as a biomarker in diagnosis and management of children with allergic rhinitis (AR). Methods: Thirty children diagnosed with symptoms and allergen-specific IgE detection were extracted as the AR group

13 children with allergic rhinitis symptoms and allergic history or allergic family history were recruited as the suspected AR (SAR) group

and 12 healthy children without nasal symptoms and allergic family history were recruited as the normal group. The Sunvou exhaled NO measurement system was adopted

the nasal passive exhalation + mute technology were used to detect the nNO level of each group. The AR group was treated with fluticasone propionate nasal spray for two weeks

and the efficacy was evaluated

the levels of nNO were detected. The levels of nNO were compared among three groups

as well as before and after treatment in the AR group. Results: There was no statistically significant difference in age and gender among three groups (P>0.05). The levels of nNO of the AR group

the SAR group and the normal group were respectively (842±133) ppb

(569±44) ppb

and (289±33) ppb

and the levels nNO of the AR group and the SAR group were higher than those of the normal group (P<0.05). The symptoms of 12 cases in the AR group were improved after treatment with fluticasone propionate nasal spray

and the levels of nNO after treatment were lower than those before treatment (P<0.05). Conclusion: nNO detection has certain clinical value for the diagnosis and follow-up of AR

and the auxiliary diagnosis of AR requires comprehensive consideration of the condition of rhinitis and paranasal sinuses.